CN102603610B - 1,3-dihydro-1-oxo-2H-isobenzazole compounds as well as preparation method and use thereof - Google Patents

1,3-dihydro-1-oxo-2H-isobenzazole compounds as well as preparation method and use thereof Download PDF

Info

Publication number
CN102603610B
CN102603610B CN201210038183.7A CN201210038183A CN102603610B CN 102603610 B CN102603610 B CN 102603610B CN 201210038183 A CN201210038183 A CN 201210038183A CN 102603610 B CN102603610 B CN 102603610B
Authority
CN
China
Prior art keywords
oxygen
dihydro
isoindole
reaction
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201210038183.7A
Other languages
Chinese (zh)
Other versions
CN102603610A (en
Inventor
邓勇
金晓董
黄志雄
吴成龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan University
Original Assignee
Sichuan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan University filed Critical Sichuan University
Priority to CN201410270438.1A priority Critical patent/CN104045594B/en
Priority to CN201210038183.7A priority patent/CN102603610B/en
Publication of CN102603610A publication Critical patent/CN102603610A/en
Application granted granted Critical
Publication of CN102603610B publication Critical patent/CN102603610B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention discloses 1,3-dihydro-1-oxo-2H-isobenzazole compounds (I) and pharmaceutically acceptable salts thereof, and also discloses preparation methods for the compounds, and uses of the compounds in preparing medicines for preventing and/or treating various diseases caused by the mediation of integrin alpha v beta 3, such as tumor metastasis, tumor growth, solid tumor growth, angiogenesis, retinopathy, macular degeneration, osteoporosis, arthritis, smooth muscle cell migration and atherosclerosis symptoms or diseases.

Description

1,3-dihydro-1-oxygen-2H-isoindoles compound, Preparation Method And The Use
Technical field
The invention belongs to pharmaceutical chemistry field, relate to a class 1,3-dihydro-1-oxygen-2H-isoindoles compound (I) and pharmacy acceptable salt thereof, its preparation method, pharmaceutical composition and in preparation prevention or/and treat various because of integrin alpha vβ 3mediate the purposes in caused symptom or disease medicament, include but not limited to metastases, tumor growth, implanted solid tumor growth, angiogenesis, retinopathy, macular degeneration, osteoporosis, sacroiliitis, smooth muscle cell migration and atherosclerosis etc.
Background technology
Angiogenesis (angiogenesis) refers to the process that produces new vessel system from already present vescular bed, in normal physiological situation, vasculogenesis is strictly controlled in some of short duration, specific physiological process, as reproduction, growth course and wound healing process etc., and the vasculogenesis of survival is some pathology, as the characteristic of the malignancy of: tumor tissues, retinopathy, macular degeneration, sacroiliitis, osteoporosis etc.Research shows, the angiogenesis of tumor inducing and the propagation of tumour cell, invade profit and shift closely related, new vessel is not only for the malignancy of tumour cell provides sufficient nutrient material, but also for shifting, the amphi position of tumour cell provides path, therefore, suppressing the angiogenesis of tumor inducing, reduce or the blood supply of blocking-up tumor tissues and tumour cell " is died of hunger ", is the effective way of preventing and treating metastases.This starvation cure is compared with traditional cell toxicant series antineoplastic medicament, because anti-angiogenic drugs is to make tumor cell proliferation cycle stretch-out by the blood supply reducing or block tumor tissues, promote tumour cell necrosis and work, rather than directly kill tumour cell, therefore, this class medicine without obvious toxic-side effects, shows good tumor-targeting to normal cell; And this therapy can overcome the resistance problem in traditional chemotherapeutics therapeutic process, and resistance is one of major reason of current chemotherapeutic treatment means failure.
Study and show recently, the effect of the angiogenesis of tumor inducing and the transfer of tumour and integrin (Integrins) is closely related.Integrin belongs to cell surface adhesion molecule family, the heterodimer transmembrane glycoprotein being formed by connecting by non covalent bond by α and two subunits of β.Find altogether up to now more than 20 kind of integrin hypotype, different hypotypes has different cell characteristics and adhesion characteristics, they are by mediated cell and cell, cell and extracellular matrix (extracellular matrix, the signal transduction of adhesion ECM) and participation cell, and adhesion to cell, propagation, transfer, apoptosis etc. play important regulating and controlling effect, wherein integrin alpha vβ 3in the processes such as the vasculogenesis of tumor growth, local infiltration, transfer, particularly tumor inducing, play an important role.
Integrin alpha vβ 3by α vand β 3two subunit compositions, are divided into extracellular region, cross-film district and intracellular region three parts, wherein α vsubunit has 1018 amino-acid residues, molecular weight 125kD, β 3subunit has 762 amino-acid residues, molecular weight 105kD; To integrin alpha vβ 3extracellular region and showing with the crystalline structure research of ligand complex, its extracellular region is made up of 12 structural domains, and wherein the N-terminal part of α and β subunit is assembled into avette " head ", extends two almost parallel " tails " from " head "; The combination of part occurs in the zone of action of α and β subunit, and ligand binding domain mainly comprises β-propeller structural domain of α subunit and the β of β subunit astructural domain, and need the participation of divalent cation, positively charged ion in ligand binding not only with acidic-group effect mediation part and the α of part vβ 3combination, can also stable alpha vβ 3ligand binding surface.Integrin alpha vβ 3cerebrospinal fluid be containing Arg-Gly-Asp (Arg-Gly-Asp in extracellular matrix components (as: fibronectin (fibronectin), laminin (laminin), hyaluronectin (vitronectin) and thrombospondin (thromobospondin) etc.), RGD, 1) sequence of tripeptides, and the identification of extracellular matrix composition has selectivity, work as α vβ 3after RGD in matrix components is combined, the protein kinase approach activating by mitogen makes vascular endothelial cell proliferation, differentiation and migration, promotes tube chamber to form and becomes new vessel.Experiment showed, and use exogenous sequence peptide or analogue containing RGD, adhesion and migration, inducing apoptosis of tumour cell and inhibition neonate tumour blood vessel that can inhibition tumor cell, finally cause tumor growth to be suppressed, even tumor regression.Due to integrin alpha vβ 3in normal vascular endothelial cell and most normal organ system, seldom express, be just subject to angiogenesis factor (angiogenic growth factors) and stimulate high expression level on the osteoclast of the vascular endothelial cell of lower activation, activation and invasive tumour cell; And new vessel endotheliocyte belongs to the non-malignant cell of inheritance stability, the α that it is surperficial vβ 3acceptor is not undergone mutation, with inhibitor mechanism in can not produce resistance problem; In addition, α vβ 3acceptor is positioned at cell surface, directly contacts with blood, and medicine is easy to arrive target spot; Therefore, integrin alpha vβ 3that design is efficient, anti-angiogenic rebirth and the comparatively ideal target of medicine for anti transfer of tumor of highly selective.
Find integrin alpha vβ 3inhibitor, for finding that anti-angiogenic rebirth and medicine for anti transfer of tumor are significant, can also be used for the treatment of because of common diseases such as tumor growth, implanted solid tumor growth, retinopathy, macular degeneration, osteoporosis, sacroiliitis, smooth muscle cell migration and atherosclerosiss that new vessel hyperplasia causes.
Figure BDA0000136974450000021
At present, with integrin alpha vβ 3for the anti-angiogenic rebirth of action target spot and medicine for anti transfer of tumor are still in the clinical or preclinical test stage, these inhibitor can be divided three classes, that is: monoclonal antibody, polypeptide and cyclic peptide and stand-in thereof, non-peptide micromolecular.Vitaxin and Vitaxin II are the α of Eli Lilly company exploitation vβ 3monoclonal antibody, can with integrin alpha vβ 3specific binding, suppresses tumor growth and angiogenesis, is just carrying out at present II clinical trial phase, is used for treating melanoma, Advanced Colon Cancer and the rheumatic arthritis of prostate cancer, transfer.Research is found, uses exogenous linear peptides or pdef polypeptide containing RGD sequence, as: RGDS, GRGDS, poly-RGDS etc. can stop the angiogenesis of bFGF, TNF-α and the various tumor fragments inductions of people, and on already present blood vessel without impact.But these peptide quasi-molecules are flexible strong, cause integrin alpha vβ 3the selectivity of acceptor and avidity are all poor.Cyclic peptide, because its conformation is within the specific limits in bond, therefore has good selectivity to different integrins.Cyclic peptide cyclo (RGDfV) (Cyclo (Arg-Gly-Asp-D-Phe-Val-), 2) is the integrin alpha of a kind of high reactivity and highly selective vβ 3inhibitor, its vitro inhibition α vβ 3the IC of being combined with its ligandin 50for 2.5nmol/L; The researchist of Merck company methylates cyclo (RGDfV) peptide chain backbone on this basis, obtain more highly active polypeptide stand-in cyclo (RGDf-N (Me) V) (3, popular name Cilengitide), its IC 50for 0.58nmol/L, can antagonism integrin alpha vβ 3the vascular endothelial cell of mediation and the interaction of extracellular matrix, the growth of check melanin knurl and angiogenesis, and can induce the apoptosis of the brain tumor cell of growing on vitronectin, Cliengitide is carrying out II/III clinical trial phase at present, is used for the treatment of lung cancer, carcinoma of the pancreas, mammary cancer, melanoma, tumor of kidney and colorectal carcinoma.Because antibody and peptide medicament exist, vivo degradation, transformation period are short, the low deficiency such as intravenously administrable, a large amount of preparation difficulties that needs of bioavailability, therefore, find and find non-peptide class integrin alpha efficient, highly selective Orally-administrable vβ 3inhibitor is one of key areas that anti-angiogenic rebirth and medicine for anti transfer of tumor are studied both at home and abroad at present.
Summary of the invention
The object of the invention is to disclose a class and have the integrin alpha of 1,3-dihydro-1-oxygen-2H-isoindoles chemical structure (I) vβ 3inhibitor or its pharmacy acceptable salt.
Another object of the present invention is to disclose this 1, the preparation method of 3-dihydro-1-oxygen-2H-isoindoles compound (I).
Another object of the present invention is openly to comprise the pharmaceutical composition of 1,3-dihydro-1-oxygen-2H-isoindoles compound (I) or its pharmacy acceptable salt.
A further object of the present invention is to disclose 1,3-dihydro-1-oxygen-2H-isoindoles compound (I) or its pharmacy acceptable salt prevents or/and treat various because of integrin alpha in preparation vβ 3mediate the purposes in caused symptom or disease medicament, include but not limited to metastases, tumor growth, implanted solid tumor growth, angiogenesis, retinopathy, macular degeneration, osteoporosis, sacroiliitis, smooth muscle cell migration and atherosclerosis etc.
Provided by the invention 1, the chemical structure of general formula of 3-dihydro-1-oxygen-2H-isoindoles compound (I) is:
Figure BDA0000136974450000031
In formula: R 1represent H, phenyl, 2-furyl, 2-thienyl, 3-thienyl, 3-pyridyl, 4-pyridyl, 3,4-methylenedioxyphenyl base, 2,3-methylenedioxyphenyl base,
Figure BDA0000136974450000032
or
Figure BDA0000136974450000033
r 3, R 4, R 5represent independently of one another H, C 1～C 6alkyl, C 1～C 6alkoxyl group, hydroxyl, halogen, amino, nitro, cyano group, carboxyl, CF 3, NR 7r 8, R 6represent H, C 1～C 6alkyl, C 1～C 6alkoxyl group, halogen, nitro, cyano group or CF 3, R 7, R 8represent independently of one another C 1～C 6alkyl, R 3, R 4, R 5, R 6can be at any possible position of phenyl ring, R 3, R 4, R 5can be identical, also can be different; R 2represent
Figure BDA0000136974450000041
Figure BDA0000136974450000042
n represents that 1-3, m represent 0-2, R 9represent C 1～C 6alkyl, halogen, hydroxyl or CF 3.
For disclosed in this invention 1, while there is chiral carbon in 3-dihydro-1-oxygen-2H-isoindoles compound (I) molecule, compound (I) is raceme or optically active body.
Disclosed in this invention 1,3-dihydro-1-oxygen-2H-isoindoles compound (I) can prepare by the following method:
Figure BDA0000136974450000043
In formula: R 1and R 2definition identical with chemical structure of general formula (I);
Take 2-formyl radical-5-nitrobenzoic acid (4) and Beta-alanine methyl esters analog derivative (5) as starting raw material, in suitable solvent through reduction, cyclization obtains 3-(6-nitro-1-oxygen isoindole-2-yl) methyl propionate (6), gained intermediate (6) is amino with reductive agent by nitroreduction, obtain 3-(6-amino-1-oxygen isoindole-2-yl) methyl propionate (7), then with carboxylic acid compound (8) condensation under condensing agent existence condition that contains guanidine radicals, obtain 1, 3-dihydro-1-oxygen-2H-isoindole methyl esters compounds (9), again through basic hydrolysis, acid neutralization, obtain 1, 3-dihydro-1-oxygen-2H-isoindoles compound (I).
The each reactions steps of aforesaid method specifically describes as follows:
A), take 2-formyl radical-5-nitrobenzoic acid (4) and Beta-alanine methyl esters analog derivative (5) as starting raw material, in suitable solvent, obtain 3-(6-nitro-1-oxygen isoindole-2-yl) methyl propionate (6) through reduction, cyclization; Wherein, reaction solvent for use is: C 1-8fatty alcohol, DMF, ethers (as: ether, isopropyl ether, methyl tertiary butyl ether, tetrahydrofuran (THF), glycol dimethyl ether etc.), C 1-6lipid acid, C 1-6lipid acid and C 1-6ester that fatty alcohol forms, halohydrocarbon (as: methylene dichloride, chloroform, 1,2-ethylene dichloride etc.), aromatic hydrocarbon or substituted aroma hydrocarbon (as: benzene,toluene,xylene, chlorobenzene, orthodichlorobenzene etc.) or acetonitrile, be preferably methyl alcohol, ethanol, acetic acid, ethyl acetate, ether, methylene dichloride or tetrahydrofuran (THF); Reductive agent used is: KBH 4, NaBH 4, LiBH 4, NaBH 3cN, preferably reductive agent is NaBH 4, KBH 4; The molar feed ratio of 2-formyl radical-5-nitrobenzoic acid (4), Beta-alanine methyl esters analog derivative (5) and reductive agent is 1.0: 1.0～5.0:0.5～5.0, and preferably molar feed ratio is 1.0: 1.1～3.0: 1.0～3.0; Temperature of reaction is-20 ℃～120 ℃, is preferably 0 ℃～100 ℃; Reaction times is 30 minutes～72 hours, is preferably 1～15 hour.
By steps A) 3-(6-nitro-1-oxygen isoindole-2-yl) methyl propionate (6) that obtains is in suitable solvent, through chemical reduction or catalytic hydrogenation reduction, be amino by nitroreduction, obtain 3-(6-amino-1-oxygen isoindole-2-yl) methyl propionate (7); Wherein, while using chemical reduction method, reaction solvent for use is: C 1～C 6fatty alcohol, tetrahydrofuran (THF), ether, C 1-6lipid acid, C 1-6lipid acid and C 1-6ester that fatty alcohol forms, benzene, toluene, 1,4-dioxane, glycol dimethyl ether, methylene dichloride, chloroform, 1, the aqueous hydrochloric acid that 2-ethylene dichloride, concentration are 1%-36%, the aqueous ammonium chloride solution that concentration is 1%-30% or the mixture of above-mentioned solvent, be preferably methyl alcohol, ethanol, acetic acid, ethyl acetate, ether, methylene dichloride or tetrahydrofuran (THF); Reductive agent used is: zinc powder, iron powder or tindichloride; Compound (6) is 1.0: 1.0～10.0 with the molar feed ratio of reductive agent, and preferably molar feed ratio is 1.0: 1.5～5.0; Temperature of reaction is 0 ℃～150 ℃, and preferable reaction temperature is room temperature～solvent refluxing temperature; The reduction reaction time is 0.5～72 hour, and the preferred reaction time is 1～12 hour;
While adopting catalytic hydrogenation reduction, reaction solvent for use is: C 1-8fatty alcohol, ether, isopropyl ether, methyl tertiary butyl ether, tetrahydrofuran (THF), glycol dimethyl ether, C 1-6lipid acid, C 1-6lipid acid and C 1-6ester that fatty alcohol forms, benzene,toluene,xylene or acetonitrile, be preferably methyl alcohol, ethanol, acetic acid or ethyl acetate; Used catalyst is: 1%～30%Pd-C, 1%～30%Pd (OH) 2-C, Raney-Ni, preferred catalyst is: Raney-Ni, 5%～20%Pd-C, 5%～20%Pd (OH) 2-C; Compound (6) is 1.0: 0.01～1.0 with the mass ratio of catalyzer; Reaction pressure is normal pressure～10.0MPa, is preferably normal pressure～2.0MPa; Temperature of reaction is room temperature～150 ℃, is preferably room temperature～80 ℃; Reaction times is 1～48 hour, is preferably 1～24 hour.
By step B) 3-(6-amino-1-oxygen isoindole-2-yl) methyl propionate (7) that obtains in suitable solvent with carboxylic acid compound (8) condensation under condensing agent existence condition containing guanidine radicals, obtain 1,3-dihydro-1-oxygen-2H-isoindole methyl esters compounds (9), wherein, reaction solvent for use is: pyridine, DMF, C 3-8aliphatic ketone, ethers (as: ether, isopropyl ether, methyl tertiary butyl ether, tetrahydrofuran (THF), glycol dimethyl ether etc.), C 1-6lipid acid and C 1-6ester that fatty alcohol forms, halohydrocarbon (as: methylene dichloride, chloroform, 1,2-ethylene dichloride etc.), aromatic hydrocarbon or substituted aroma hydrocarbon (as: benzene,toluene,xylene, chlorobenzene, orthodichlorobenzene etc.) or acetonitrile, reaction can be carried out in above-mentioned single solvent, also can in above-mentioned mixed solvent, carry out, mixed solvent volume ratio is 1: 0.1～10, preferred solvent is pyridine, tetrahydrofuran (THF), DMF, acetone, chlorobenzene or acetonitrile, condensing agent used is: chloroformic acid C 1-8aliphatic alcohol ester compounds (as: Vinyl chloroformate, the chloroformic acid tert-butyl ester, chloroformic acid benzyl ester etc.), N-ethoxycarbonyl-2-oxyethyl group-1, 2-dihydroquinoline (EEDQ), carbodiimide compound (as: dicyclohexylcarbodiimide (referred to as DCC), 1-ethyl-3-(3-dimethylamine propyl) carbodiimide hydrochloride (referred to as EDCI)), diethyl phosphorocyanidate (DEPC), 2-chloro-4, 6-dimethoxy-1, 3, 5-triazine (referred to as CDMT), chlorination 4-(4, 6-dimethoxy-1, 3, 5-triazine-2-yl)-4-methylmorpholine salt (referred to as DMTMM), wherein, negatively charged ion in DMTMM is chlorine, bromine, perchlorate, fluoroboric acid root, methanesulfonic base, Phenylsulfonic acid base, tosic acid base, camphorsulfonic acid base, sulfamide groups, preferably condensing agent is: Vinyl chloroformate, dicyclohexylcarbodiimide (DCC), EDCI, DMTMM, compound (7): compound (8): the molar feed ratio of condensing agent is 1.0: 1.0～4.5: 1.0～4.5, preferably molar feed ratio is 1.0: 1.0～2.0: 1.0～2.0, setting-up point is 0～130 ℃, and preferable reaction temperature is 0～50 ℃, condensation reaction time is 30 minutes～72 hours, and the preferred reaction time is 2～48 hours.
By step C) obtain 1,3-dihydro-1-oxygen-2H-isoindole methyl esters compounds (9) is through basic hydrolysis, acid neutralization, obtain 1,3-dihydro-1-oxygen-2H-isoindoles compound (I), gained (I), again according to ordinary method and corresponding sour salify, obtains the salt of compound (I); Wherein, being hydrolyzed alkali used is basic metal or alkaline earth metal hydroxides, basic metal or alkaline earth metal carbonate, basic metal or alkali metal bicarbonates, and preferred bases is: lithium hydroxide, sodium carbonate; The molar feed ratio of alkali and compound (9) is 1.0～5.0: 1.0, and preferably molar feed ratio is 1.1～2.5: 1.0; Hydrolysising reacting temperature is room temperature～150 ℃, and preferable reaction temperature is room temperature reaction; Hydrolysis time is 0.5～24 hour, and the preferred reaction time is 1～7 hour.
Disclosed in this invention 1,3-dihydro-1-oxygen-2H-isoindoles compound (I) can obtain acceptable salt on its pharmacology by pharmaceutically conventional salifying method with any suitable acid, and described acid is hydrochloric acid, Hydrogen bromide, nitric acid, sulfuric acid, phosphoric acid, formic acid, trifluoroacetic acid, acetic acid, propionic acid, oxalic acid, phenylformic acid, toxilic acid, fumaric acid, succsinic acid, tartrate, amygdalic acid, citric acid, methylsulphonic acid, ethylsulfonic acid, camphorsulfonic acid, Phenylsulfonic acid or tosic acid.
The common technology of starting raw material of the present invention---2-formyl radical-5-nitrobenzoic acid (4) and the available this area of Beta-alanine methyl esters analog derivative (5) makes, including, but not limited to disclosed method: 1.R.L.Shriner in Publication about Document, F.J.Wolf.Org.Syn.Coll.Vo1.3 (1955) 737; 2.V.T.Abaev, A.S.Dmitriev, A.V.Gutnov J.Heterocyclic Chem., 43 (2006) 1195; 3.C.Y.K.Tana, D.F.Weaver.Tetrahedron58 (2002) 7449.
Pharmaceutical composition disclosed in this invention comprise treatment significant quantity one or more 1,3-dihydro-1-oxygen-2H-isoindoles compound (I) or its pharmacy acceptable salt, this pharmaceutical composition can further contain one or more pharmaceutically acceptable carrier or vehicle.Described " treatment significant quantity " refer to cause investigator or doctor for biological or the medicine of medicine reaction or the amount of medicament of tissue, system or animal; Described " composition " refers to by more than one materials or component are mixed to the product forming; Described " pharmaceutically acceptable carrier " refers to pharmaceutically acceptable material, composition or carrier, as: liquid or solid weighting agent, thinner, vehicle, solvent or packing material, they carry or transport certain chemical substance.
Proposed by the invention 1,3-dihydro-1-oxygen-2H-isoindoles compound (I) or its pharmacy acceptable salt have carried out following bioactivity screening:
(1) solid phase receptor screening
Screening is carried out in 96 well culture plates.Integrin alpha vβ 3coating Buffer solution (Tris-HCl20mM, NaCl150mM, CaCl for albumen 21mM and NaN 30.02%) being made into concentration is 4 μ g/mL, add in 96 orifice plates, every hole 100 μ L, 4 ℃ of coated spending the night, negative control is coated with method with 2%BSA, abandoning supernatant, every hole adds the 2%BSA of 100 μ L, and Binding Buffer solution (Tris-HCl50mM, CaCl are used in 37 ℃ of sealings after 1 hour 22mM, NaN 30.02% and BSA1mg/mL (0.1%)) clean.Compound to be screened is become to different concns with Binding Buffer solution dilution, taking biotin labeled Bio-Fibronectin solution (8 μ g/mL) mixes with the compound to be screened of different concns, add in 96 orifice plates, every hole 100 μ L, negative control group and model group add equivalent Binding Buffer solution, hatch 3 hours for 37 ℃, after cleaning with Binding Buffer solution, every hole adds the HRP-Streptavidin (1: 500) of 100 μ L, hatch 1 hour for 37 ℃, with Binding Buffer solution cleaning three times, every hole adds 3 of 100 μ L, 3 ', 5, 5 '-tetramethyl benzidine stoste (TMB), incubated at room 10 minutes, then add 1.0M sulphuric acid soln (every hole 100 μ L) termination reaction, in microplate reader, measure each hole OD value (wavelength is 450nm), calculate compound to be screened and integrin alpha vβ 3the combination inhibiting rate of albumen, inhibiting rate (%)=[1-(being subject to test product OD value-feminine gender group OD)/(the negative group of model group OD-OD)) × 100.
Utilize aforesaid method, measured target compound to integrin alpha vβ 3the avidity of albumen, it is disclosed in this invention 1 that result shows, 3-dihydro-1-oxygen-2H-isoindoles compound (I) or its pharmacy acceptable salt and integrin alpha vβ 3the combination of albumen suppresses IC 50at 1.8nM～2000nM, and the IC of positive control drug cyclo (RGDfV) 50for 10.0nM.
(2) the inhibiting mensuration of cell adhesion
96 well culture plates are coated with and spend the night with the Fibronectin of 2.0 μ g/mL, and control wells is coated with 1%BSA, abandoning supernatant, and every hole adds the 1%BSA of 100 μ L, room temperature sealing 1 hour.Compound to be screened is made into different concns with the PBS solution of 0.01M, and adding concentration is 5 × 10 5in the M21 cell suspension of/ml, cyclo for positive control (RGDfV), blank replaces with the PBS solution of 0.01M, hatch 30 minutes for 37 ℃, then M21 cell suspension is added in 96 well culture plates of above-mentioned sealing in advance, every hole 100 μ L, hatch 1 hour for 37 ℃, cell suspension in sucking-off hole gently, wash 3 times with the PBS of pre-temperature, remove the cell not adhering to, every hole adds 10% glutaraldehyde of 100 μ L to fix 30 minutes, thoroughly clean to glutaraldehyde with deionized water wash, put 37 ℃ of baking oven finish-dryings, add 0.1% Viola crystallina to dye to cell, jolting 30 minutes, with distilled water, unnecessary Viola crystallina is clean, put 37 ℃ of baking oven finish-dryings, add 10% acetic acid to extract the Viola crystallina of Cell uptake, after 1 hour, in microplate reader, measure OD value (wavelength is 595nm), calculate cell adhesion inhibiting rate, can show that target compound is to integrin alpha vβ 3inhibition activity.Utilize aforesaid method, measured the adherence inhibition activity of part target compound to M21 cell, it the results are shown in embodiment 10.
(3) mensuration of target compound cytotoxic activity
To be caused by cell toxicant factor in order to get rid of target compound to the anti-cell adhesive activity of M21 cell, for this reason, we have tested the inhibition activity of target compound to human liver cancer cell HepG2, human A549 cell lines, B16 mouse melanoma cell line, human melanoma cell M21 and mouse colonic cell C26.Tumour cell is digested respectively to counting, and be inoculated in 96 orifice plates (5000 cells/well), PBS liquid with pH7.4 after 24 hours washs 2 times, add the medicine containing different concns, cultivate 48 hours, after washing, with dyeing 15 minutes under 0.4% sulphonyl rhodamine (SRB) solution room temperature, 1% Glacial acetic acid is washed 3 times, in air, the cell of dyeing is dry, Tris-HCl with 10mM dissolves, and surveys the absorbance of 540nm wavelength with Dynatech MR7000 instrument, calculates the inhibiting rate of medicine to growth of tumour cell.
Test-results shows, disclosed in this invention 1,3-dihydro-1-oxygen-2H-isoindoles compound (I) or the IC of its pharmacy acceptable salt to these inhibiting tumour cells 50all be greater than 80 μ g/mL, illustrate that the cell toxicant of this compounds is less.
Disclosed in this invention 1,3-dihydro-1-oxygen-2H-isoindoles compound (I) or its pharmacy acceptable salt have significant integrin alpha vβ 3suppress active, can be used as integrin alpha vβ 3inhibitor or/and treat the various purposes because of the caused symptom of new vessel hyperplasia or disease medicament, includes but not limited to metastases, tumor growth, implanted solid tumor growth, angiogenesis, retinopathy, macular degeneration, osteoporosis, sacroiliitis, smooth muscle cell migration and atherosclerosis etc. for preventing.
Embodiment
Can conduct further description the present invention by the following examples, but scope of the present invention is not limited to following embodiment.One of skill in the art can understand, and is not deviating under the prerequisite of the spirit and scope of the present invention, can carry out various variations and modification to the present invention.
Embodiment 1
The preparation of 3-(6-(3-guanidinobenzamides base)-1-oxygen isoindole-2-yl)-3-phenylpropionic acid hydrochloride (I-1) and trifluoroacetate
Figure BDA0000136974450000081
Step (a): add 2-formyl radical-5-nitrobenzoic acid (4) 10.0mmol, beta-phenyl-Beta-alanine methyl esters 12.0mmol and methyl alcohol 80ml in reaction flask, stirring at room temperature reaction 2.0h, puts the cooling lower NaBH that slowly adds of ice-water bath 410.0mmol, insulated and stirred reaction (reaction process is monitored with TLC), after reaction finishes, remove solvent under reduced pressure, in resistates, add acetic acid 20ml, 80 ℃ of insulation reaction 40min, in reaction flask, add deionized water 100ml, the solid that filtration is separated out, filter cake washs with aqueous sodium carbonate, dry, obtain 3-(6-nitro-1-oxygen isoindole-2-yl)-3-phenylpropionic acid methyl esters, yield 90.0%, ESI-MS (m/z ,+Q): 341.0[M+H] +;
Step (b): add 3-(6-nitro-1-oxygen isoindole-2-yl)-3-phenylpropionic acid methyl esters 10.0mmol and methyl alcohol 200ml in reaction flask, after stirring, add 10%Pd/C0.5g, with after air in hydrogen exchange reaction flask, under normal temperature and pressure, logical hydrogen reduction reaction 12h (monitor with TLC by reaction process, petrol ether/ethyl acetate=1: 2v/v), after reaction finishes, filter, filtrate decompression is steamed and is desolventized, resistates is through recrystallization or column chromatography purification, obtain 3-(6-amino-1-oxygen isoindole-2-yl)-3-phenylpropionic acid methyl esters, yield 99.0%, ESI-MS (m/z, + Q): 311.1[M+H] +,
Step (c): add 3-(6-amino-1-oxygen isoindole-2-yl)-3-phenylpropionic acid methyl esters 1.0mmol in reaction flask, between guanidinobenzoic acid hydrochloride 1.2mmol and pyridine 25ml, stirring at room temperature to solid complete molten after, add 1-ethyl-3-(3-dimethylamine propyl) carbodiimide hydrochloride 1.5mmol, stirring at room temperature 24～48h (monitor with TLC by reaction process, chloroform/methanol=5: 1v/v), after reaction finishes, filter, filtrate decompression is steamed and is desolventized, resistates is through recrystallization or column chromatography purification, obtain 3-(6-(3-guanidinobenzamides base)-1-oxygen isoindole-2-yl)-3-phenylpropionic acid methyl ester hydrochloride, yield 80.5%, ESI-MS (m/z, + Q): 472.1[M-Cl] +,
Step (d): add 3-(6-(3-guanidinobenzamides base)-1-oxygen isoindole-2-yl)-3-phenylpropionic acid methyl ester hydrochloride 0.5mmol in reaction flask, methyl alcohol 10ml, tetrahydrofuran (THF) 5ml and deionized water 5ml, after stirring at room temperature is even, add lithium hydroxide 2.0mmol, stirring at room temperature reaction 1.5h (monitor with TLC by reaction process, chloroform/methanol/HOAc=3/1/0.5v/v), after reaction finishes, with 10% aqueous hydrochloric acid regulator solution pH to 1-2, remove solvent under reduced pressure, resistates is through recrystallization or column chromatography purification, obtain 3-(6-(3-guanidinobenzamides base)-1-oxygen isoindole-2-yl)-3-phenylpropionic acid hydrochloride, yield 65.0%, 1h NMR (400MHz, DMSO-d 6) δ: 12.45 (brs, 1H, COOH) 10.64 (s, 1H, CONH), 10.52 (brs, 1H, HCl), 8.21 (d, 1H, J=1.6Hz, Ar-H), 7.95 (dd, 1H, J 1=1.6Hz, J 2=8.4Hz, Ar-H), 7.89 (d, 1H, J=8.0Hz, Ar-H), 7.86 (s, 1H, Ar-H), 7.69 (brs, 4H, NH 2c (NH) NH), 7.59 (d, 1H, J=8.0Hz, Ar-H), 7.59 (t, 1H, J=8.0Hz, Ar-H), 7.53 (d, 1H, J=8.0Hz, Ar-H), 7.43 (d, 2H, J=8.0Hz, Ar-H), 7.41-7.27 (m, 5H, Ar-H), 5.76 (t, 1H, J=8.0Hz, CH), 4.51 (d, 1H, J=17.6Hz, ArCH 2), 4.14 (d, 1H, J=17.6Hz, ArCH 2), 3.18-3.05 (m, 2H, CH 2cOOH), ESI-MS (m/z): 458.10[M-Cl] +,
In above-mentioned steps (d), hydrolysis finishes rear with trifluoroacetic acid regulator solution pH to 1-2, remove solvent under reduced pressure, resistates is through recrystallization or column chromatography purification, obtain 3-(6-(3-guanidinobenzamides base)-1-oxygen isoindole-2-yl)-3-phenylpropionic acid trifluoroacetate, yield 60.0%.
Embodiment 2
The preparation of 3-(6-(4-guanidinobenzamides base)-1-oxygen isoindole-2-yl)-3-phenylpropionic acid hydrochloride (I-2)
Figure BDA0000136974450000091
Operating process is with embodiment 1, just guanidinobenzoic acid hydrochloride between in step (c) is substituted with p-guanidinobenzoic acid hydrochloride, condensing agent 1-ethyl-3-(3-dimethylamine propyl) carbodiimide hydrochloride substitutes with DCC, obtain 3-(6-(4-guanidinobenzamides base)-1-oxygen isoindole-2-yl)-3-phenylpropionic acid hydrochloride, yield 74.0% 1h NMR (400MHz, DMSO-d 6) δ: 12.42 (brs, 1H, COOH), 11.01 (brs, 1H, HCl), 10.64 (s, 1H, CONH), 8.26 (d, 1H, J=1.6Hz, Ar-H), 8.11 (d, 2H, J=8.4Hz, Ar-H), 7.98 (dd, 1H, J 1=1.6Hz, J 2=8.0Hz, Ar-H), 7.97 (brs, 4H, NH 2c (NH) NH), 7.52 (d, 1H, J=8.0Hz, Ar-H), 7.33 (d, 2H, J=8.4Hz, Ar-H), 7.40-7.27 (m, 5H, Ar-H), 5.77 (t, 1H, J=8.0Hz, CH), 4.52 (d, 1H, J=17.6Hz, ArCH 2), 4.14 (d, 1H, J=17.6Hz, ArCH 2), 3.13-3.02 (m, 2H, CH 2cOOH); ESI-MS (m/z): 458.15[M-Cl] +.
Embodiment 3
3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] preparation of-3-phenylpropionic acid hydrochloride (I-3)
Operating process is with embodiment 1, just by guanidinobenzoic acid hydrochloride 3-[(4 between in step (c), 5-dihydro-1H-imidazoles-2-yl) amino] benzoate hydrochlorate substitute, condensing agent 1-ethyl-3-(3-dimethylamine propyl) carbodiimide hydrochloride substitutes with DCC, obtain 3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl]-3-phenylpropionic acid hydrochloride, yield 85.0% 1h NMR (400MHz, DMSO-d 6) δ: 12.44 (brs, 1H, COOH), 10.89 (s, 1H, HCl), 10.78 (s, 1H, CONH), 8.58 (s, 2H, NHCNH), 8.25 (d, 1H, J=1.2Hz, Ar-H), 7.95 (dd, 1H, J 1=1.2Hz, J 2=8.4Hz, Ar-H), 7.88-7.86 (m, 2H, Ar-H), 7.59 (t, 1H, J=8.0Hz, Ar-H), 7.53 (d, 1H, J=8.0Hz, Ar-H), 7.45 (d, 2H, J=8.0Hz, Ar-H), 7.41-7.28 (m, 5H, Ar-H), (5.76 t, 1H, J=8.0Hz, CH), 4.50 (d, 1H, J=17.6Hz, ArCH 2), 4.12 (d, 1H, J=17.6Hz, ArCH 2), 3.69 (s, 4H, CH 2cH 2), 3.23-3.09 (m, 2H, CH 2cOOH); ESI-MS (m/z): 484.20[M-Cl] +.
Embodiment 4
3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] preparation of-3-phenylpropionic acid hydrochloride (I-4)
Figure BDA0000136974450000102
Operating process is with embodiment 1, just by guanidinobenzoic acid hydrochloride 4-[(4 between in step (c), 5-dihydro-1H-imidazoles-2-yl) amino] benzoate hydrochlorate substitute, condensing agent 1-ethyl-3-(3-dimethylamine propyl) carbodiimide hydrochloride substitutes with DCC, obtain 3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl]-3-phenylpropionic acid hydrochloride, yield 78.0% 1h NMR (400MHz, DMSO-d 6) δ: 12.10 (brs, 1H, COOH), 11.00 (s, 1H, HCl), 10.51 (s, 1H, CONH), 8.75 (brs, 2H, NHCNH), (8.22 d, 1H, J=1.6Hz, Ar-H), (8.07 d, 2H, J=8.8Hz, Ar-H), 7.94 (dd, 1H, J 1=1.2Hz, J 2=8.4Hz, Ar-H), 7.54 (d, 1H, J=8.4Hz, Ar-H), 7.33 (d, 2H, J=8.8Hz, Ar-H), 7.40-7.28 (m, 5H, Ar-H), 5.76 (t, 1H, J=8.0Hz, CH), 4.51 (d, 1H, J=17.6Hz, ArCH 2), 4.13 (d, 1H, J=17.6Hz, ArCH 2), 3.69 (s, 4H, CH 2cH 2), 3.20-3.07 (m, 2H, CH 2cOOH); ESI-MS (m/z): 484.20[M-Cl] +.
Embodiment 5
3-(3,5-dichlorophenyl)-3-[6-(3-guanidinobenzamides base)-1-oxygen isoindole-2-yl] preparation of propionic salt hydrochlorate (I-5)
Figure BDA0000136974450000111
Step (a): operating process is with embodiment 1 step (a), just by beta-phenyl-Beta-alanine β-(3 for methyl esters, 5-dichlorophenyl)-Beta-alanine methyl esters substitute, obtain 3-(3,5-dichlorophenyl)-3-(6-nitro-1-oxygen isoindole-2-yl) methyl propionate, yield 82.0%, ESI-MS (m/z ,+Q): 409.0[M+H] +;
Step (b): by 3-(3,5-dichlorophenyl)-3-(6-nitro-1-oxygen isoindole-2-yl) methyl propionate 10.0mmol is dissolved in tetrahydrofuran (THF) 150ml, add acetic acid 25ml and zinc powder 160.0mmol, reflux 4h (reaction process is monitored with TLC, petrol ether/ethyl acetate=1: 2v/v), after reaction finishes, be cooled to room temperature,, filter to alkalescence with saturated sodium bicarbonate aqueous solution regulator solution pH, filtrate is with 3 × 70ml CH 2cl 2extraction, merges organic layer and uses saturated common salt water washing, and organic layer is through anhydrous Na S0 4dry, remove solvent under reduced pressure, resistates is through recrystallization or column chromatography purification, obtain 3-(3,5-dichlorophenyl)-3-(6-amino-1-oxygen isoindole-2-yl) methyl propionate, yield 96.0%, ESI-MS (m/z ,+Q): 365.1[M+H] +;
Step (c): operating process is with embodiment 1 step (c), just by 3-(6-amino-1-oxygen isoindole-2-yl)-3-phenylpropionic acid 3-(3 for methyl esters, 5-dichlorophenyl)-3-(6-amino-1-oxygen isoindole-2-yl) methyl propionate substitute, obtain 3-(3,5-dichlorophenyl)-3-[6-(3-guanidinobenzamides base)-1-oxygen isoindole-2-yl] methyl propionate hydrochloride, yield 80.0%, ESI-MS (m/z ,+Q): 540.0[M-Cl] +;
Step (d): operating process is with embodiment 1 step (d), just by 3-(6-(3-guanidinobenzamides base)-1-oxygen isoindole-2-yl)-3-phenylpropionic acid 3-(3 for methyl ester hydrochloride, 5-dichlorophenyl)-3-[6-(3-guanidinobenzamides base)-1-oxygen isoindole-2-yl] methyl propionate hydrochloride substitute, obtain 3-(3,5-dichlorophenyl)-3-[6-(3-guanidinobenzamides base)-1-oxygen isoindole-2-yl] propionic salt hydrochlorate, yield 93.0% 1h NMR (400MHz, DMSO-d 6) δ: 12.53 (brs, 1H, COOH), 10.62 (s, 1H, HCl), 10.12 (s, 1H, CONH), 8.23 (d, 1H, J=1.2Hz, Ar-H), 7.96 (dd, 1H, J 1=2.0Hz, J 2=8.4Hz, Ar-H), 7.91 (d, 1H, J=8.0Hz, Ar-H), 7.87 (s, 1H, Ar-H), 7.63 (brs, 4H, NH 2c (NH) NH), 7.59 (d, 1H, J=8.0Hz, Ar-H), 7.57 (d, 1H, J=2.0Hz, Ar-H), 7.56 (d, 1H, J=8.4Hz, Ar-H), 7.48 (d, 2H, J=1.6Hz, Ar-H), 7.45 (d, 1H, J=8.0Hz, Ar-H), 5.65 (t, 1H, J=7.6Hz, CH), 4.52 (d, 1H, J=17.6Hz, ArCH 2), 4.30 (d, 1H, J=17.6Hz, ArCH 2), 3.27-3.18 (m, 2H, CH 2cOOH); ESI-MS (m/z): 526.15[M-Cl] +.
Embodiment 6
3-(3,5-dichlorophenyl)-3-[6-(4-guanidinobenzamides base)-1-oxygen isoindole-2-yl] preparation of propionic salt hydrochlorate (I-6)
Figure BDA0000136974450000121
Operating process is with embodiment 5, just guanidinobenzoic acid hydrochloride between in step (c) is substituted with p-guanidinobenzoic acid hydrochloride, condensing agent 1-ethyl-3-(3-dimethylamine propyl) carbodiimide hydrochloride substitutes with DCC, obtain 3-(3,5-dichlorophenyl)-3-[6-(4-guanidinobenzamides base)-1-oxygen isoindole-2-yl] propionic salt hydrochlorate, yield 97.0% 1h NMR (400MHz, DMSO-d 6) δ: 12.51 (brs, 1H, COOH), 10.53 (s, 1H, HCl), 10.32 (brs, 1H, CONH), 8.24 (d, 1H, J=1.6Hz, Ar-H), 8.08 (d, 2H, J=8.8Hz, Ar-H), 7.96 (dd, 1H, J 1=2.0Hz, J 2=8.4Hz, Ar-H), 7.74 (brs, 4H, NH 2c (NH) NH), 7.57 (d, 1H, J=2.0Hz, Ar-H), 7.55 (d, 1H, J=8.4Hz, Ar-H), 7.48 (d, 2H, J=1.6Hz, Ar-H), 7.38 (d, 2H, J=8.8Hz, Ar-H), 5.65 (t, 1H, J=7.6Hz, CH), 4.52 (d, 1H, J=17.6Hz, ArCH 2), 4.30 (d, 1H, J=17.6Hz, ArCH 2), 3.29-3.27 (m, 2H, CH 2cOOH); ESI-MS (m/z): 526.10[M-Cl] +.
Embodiment 7
3-(3,5-dichlorophenyl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] preparation of propionic salt hydrochlorate (I-7)
Figure BDA0000136974450000122
Operating process is with embodiment 5, just by guanidinobenzoic acid hydrochloride 3-[(4 between in step (c), 5-dihydro-1H-imidazoles-2-yl) amino] benzoate hydrochlorate substitute, condensing agent 1-ethyl-3-(3-dimethylamine propyl) carbodiimide hydrochloride substitutes with DCC, obtain 3-(3,5-dichlorophenyl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate, yield 98.0% 1h NMR (400MHz, DMSO-d 6) δ: 12.53 (brs, 1H, COOH), 10.90 (s, 1H, HCl) 10.81 (s, 1H, CONH), 8.60 (brs, 2H, NHCNH), 8.26 (d, 1H, J=2.0Hz, Ar-H), 8.01 (dd, 1H, J 1=2.0Hz, J 2=8.4Hz, Ar-H), 7.88 (d, 1H, J=8.0Hz, Ar-H), 7.87 (s, 1H, Ar-H), 7.61 (d, 1H, J=8.0Hz, Ar-H), 7.57 (d, 1H, J=8.4Hz, Ar-H), 7.56 (d, 1H, J=2.0Hz, Ar-H), 7.48 (d, 2H, J=2.0Hz, Ar-H), 7.45 (d, 1H, J=8.0Hz, Ar-H), 5.65 (t, 1H, J=7.6Hz, CH), 4.52 (d, 1H, J=17.6Hz, ArCH 2), 4.30 (d, 1H, J=17.6Hz, ArCH 2), 3.70 (s, 4H, CH 2cH 2), 3.30-3.18 (m, 2H, CH 2cOOH); ESI-MS (m/z): 552.20[M-Cl] +.
Embodiment 8
3-(3,5-dichlorophenyl)-3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] preparation of propionic salt hydrochlorate (I-8)
Figure BDA0000136974450000131
Operating process is with embodiment 5, just by guanidinobenzoic acid hydrochloride 4-[(4 between in step (c), 5-dihydro-1H-imidazoles-2-yl) amino] benzoate hydrochlorate substitute, condensing agent 1-ethyl-3-(3-dimethylamine propyl) carbodiimide hydrochloride substitutes with DCC, obtain 3-(3,5-dichlorophenyl)-3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate, yield 90.0% 1h NMR (400MHz, DMSO-d 6) δ: 12.49 (brs, 1H, COOH), 11.86 (brs, 1H, HCl), 10.58 (s, 1H, CONH), 8.85 (brs, 2H, NHCNH), 8.25 (d, 1H, J=2.4Hz, Ar-H), 8.08 (d, 2H, J=8.8Hz, Ar-H), 7.97 (dd, 1H, J 1=1.2Hz, J 2=8.0Hz, Ar-H), 7.56 (d, 1H, J=1.2Hz, Ar-H), 7.55 (d, 1H, J=8.0Hz, Ar-H), 7.47 (d, 2H, J=2.4Hz, Ar-H), 7.37 (d, 2H, J=8.8Hz, Ar-H), 5.66 (t, 1H, J=7.6Hz, CH), 4.53 (d, 1H, J=17.6Hz, ArCH 2), 4.31 (d, 1H, J=17.6Hz, ArCH 2), 3.69 (s, 4H, CH 2cH 2), 3.24-3.13 (m, 2H, CH 2cOOH); ESI-MS (m/z): 552.15[M-Cl] +.
Embodiment 9
Adopt embodiment 1～8 similar synthetic method, just corresponding reaction substrate replaced, can obtain corresponding 1,3-dihydro-1-oxygen-2H-isoindoles compound (I), its structural formula is as follows:
3-[6-(2-guanidine radicals acetamido)-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-9)
Figure BDA0000136974450000132
Yield 40.5%, ESI-MS (m/z): 320.10[M-Cl] +;
3-[6-(3-guanidine radicals propionamido-)-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-10)
Figure BDA0000136974450000133
Yield 36.0%, ESI-MS (m/z): 334.20[M-Cl] +;
3-[1-oxygen-6-[3-[(1,4,5,6-tetrahydropyrimidine-2-yl) amino] benzoylamino] isoindole-2-yl]-3-phenylpropionic acid hydrochloride (I-11)
Figure BDA0000136974450000134
Yield 79.5%, ESI-MS (m/z): 498.20[M-Cl] +;
3-[1-oxygen-6-[4-[(1,4,5,6-tetrahydropyrimidine-2-yl) amino] benzoylamino] isoindole-2-yl]-3-phenylpropionic acid hydrochloride (I-12)
Figure BDA0000136974450000141
Yield 77.0%, ESI-MS (m/z): 498.10[M-Cl] +;
3-(3,5-dichlorophenyl)-3-[1-oxygen-6-[3-[(1,4,5,6-tetrahydropyrimidine-2-yl) amino] benzoylamino] isoindole-2-yl] propionic salt hydrochlorate (I-13)
Figure BDA0000136974450000142
Yield 87.5%, ESI-MS (m/z): 566.10[M-Cl] +;
3-(3,5-dichlorophenyl)-3-[1-oxygen-6-[4-[(1,4,5,6-tetrahydropyrimidine-2-yl) amino] benzoylamino] isoindole-2-yl] propionic salt hydrochlorate (I-14)
Yield 90.0%, ESI-MS (m/z): 566.05[M-Cl] +;
3-(3,5-dichlorophenyl)-fluoro-Isosorbide-5-Nitrae of 3-[1-oxygen-6-[3-[(5-, 5,6-tetrahydropyrimidine-2-yl) amino] benzoylamino] isoindole-2-yl] propionic salt hydrochlorate (I-15)
Figure BDA0000136974450000144
Yield 85.6%, ESI-MS (m/z): 584.10[M-Cl] +;
3-(3,5-dichlorophenyl)-3-[1-oxygen-6-[3-[(5-methyl isophthalic acid, 4,5,6-tetrahydropyrimidine-2-yl) amino] benzoylamino] isoindole-2-yl] propionic salt hydrochlorate (I-16)
Figure BDA0000136974450000145
Yield 87.3%, ESI-MS (m/z): 580.20[M-Cl] +;
3-(3,5-dichlorophenyl)-3-[1-oxygen-6-[3-[(5-Trifluoromethyl-1,4,5,6-tetrahydropyrimidine-2-yl) amino] benzoylamino] isoindole-2-yl] propionic salt hydrochlorate (I-17)
Figure BDA0000136974450000151
Yield 93.5%, ESI-MS (m/z): 634.10[M-Cl] +;
3-(3,5-dichlorophenyl)-3-[1-oxygen-6-[3-[(5-hydroxyl-Isosorbide-5-Nitrae, 5,6-tetrahydropyrimidine-2-yl) amino] benzoylamino] isoindole-2-yl] propionic salt hydrochlorate (I-18)
Yield 80.5%, ESI-MS (m/z): 582.15[M-Cl] +;
3-(4-p-methoxy-phenyl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-19)
Figure BDA0000136974450000153
Yield 80.5%, ESI-MS (m/z): 514.20[M-C1] +;
3-(4-p-methoxy-phenyl)-3-[1-oxygen-6-[3-[(1,4,5,6-tetrahydropyrimidine-2-yl) amino] benzoylamino] isoindole-2-yl] propionic salt hydrochlorate (I-20)
Yield 77.3%, ESI-MS (m/z): 528.20[M-Cl] +;
3-(4-p-methoxy-phenyl)-3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-21)
Figure BDA0000136974450000155
Yield 79.5%, ESI-MS (m/z): 514.15[M-Cl] +;
3-(4-p-methoxy-phenyl)-fluoro-Isosorbide-5-Nitrae of 3-[1-oxygen-6-[3-[(5-, 5,6-tetrahydropyrimidine-2-yl) amino] benzoylamino] isoindole-2-yl] propionic salt hydrochlorate (I-22)
Figure BDA0000136974450000161
Yield 85.0%, ESI-MS (m/z): 546.30[M-Cl] +;
3-(4-bromophenyl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-23)
Figure BDA0000136974450000162
Yield 88.5%, ESI-MS (m/z): 562.20[M-Cl] +;
3-(4-bromophenyl)-3-[1-oxygen-6-[3-[(1,4,5,6-tetrahydropyrimidine-2-yl) amino] benzoylamino] isoindole-2-yl] propionic salt hydrochlorate (I-24)
Figure BDA0000136974450000163
Yield 90.0%, ESI-MS (m/z): 576.15[M-Cl] +;
3-(4-bromophenyl)-3-[1-oxygen-6-[3-[(5-Trifluoromethyl-1,4,5,6-tetrahydropyrimidine-2-yl) amino] benzoylamino] isoindole-2-yl] propionic salt hydrochlorate (I-25)
Figure BDA0000136974450000164
Yield 82.3%, ESI-MS (m/z): 644.10[M-Cl] +;
3-(3-nitrophenyl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-26)
Figure BDA0000136974450000165
Yield 75.5%, ESI-MS (m/z): 529.20[M-Cl] +;
3-(3-nitrophenyl)-3-[1-oxygen-6-[3-[(1,4,5,6-tetrahydropyrimidine-2-yl) amino] benzoylamino] isoindole-2-yl] propionic salt hydrochlorate (I-27)
Yield 73.2%, ESI-MS (m/z): 543.25[M-Cl] +;
3-(4-methoxyl group-3-nitrophenyl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-28)
Figure BDA0000136974450000172
Yield 83.2%, ESI-MS (m/z): 559.20[M-Cl] +;
3-(4-methoxyl group-3-nitrophenyl)-3-[1-oxygen-6-[3-[(1,4,5,6-tetrahydropyrimidine-2-yl) amino] benzoylamino] isoindole-2-yl] propionic salt hydrochlorate (I-29)
Figure BDA0000136974450000173
Yield 75.3%, ESI-MS (m/z): 573.15[M-Cl] +;
3-(4-dimethylin-3-nitrophenyl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-30)
Figure BDA0000136974450000174
Yield 70.0%, ESI-MS (m/z): 572.25[M-Cl] +;
3-(4-dimethylin-3-nitrophenyl)-3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-31)
Yield 68.5%, ESI-MS (m/z): 572.20[M-Cl] +;
3-(the chloro-3-nitrophenyl of 4-)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-32)
Figure BDA0000136974450000182
Yield 82.0%, ESI-MS (m/z): 563.15[M-Cl] +;
3-(the chloro-3-nitrophenyl of 4-)-3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-33)
Figure BDA0000136974450000183
Yield 75.5%, ESI-MS (m/z): 563.15[M-Cl] +;
3-(3,4-dichlorophenyl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-34)
Yield 86.0%, ESI-MS (m/z): 552.10[M-Cl] +;
3-(3,4-dichlorophenyl)-3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-35)
Figure BDA0000136974450000185
Yield 82.0%, ESI-MS (m/z): 552.20[M-Cl] +;
3-(3,4-Dimethoxyphenyl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-36)
Yield 75.0%, ESI-MS (m/z): 544.30[M-Cl] +;
3-(3,4-Dimethoxyphenyl)-3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-37)
Yield 72.9%, ESI-MS (m/z): 544.20[M-Cl] +;
3-(benzo [d] [1,3] two Evil-5-yl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-38)
Figure BDA0000136974450000193
Yield 77.5%, ESI-MS (m/z): 528.20[M-Cl] +;
3-(benzo [d] [1,3] two Evil-5-yl)-3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-39)
Figure BDA0000136974450000194
Yield 69.5%, ESI-MS (m/z): 528.10[M-Cl] +;
3-(benzo [d] [1,3] two Evil-4-yl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-40)
Figure BDA0000136974450000201
Yield 65.6%, ESI-MS (m/z): 528.05[M-Cl] +;
3-(benzo [d] [1,3] two Evil-4-yl)-3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-41)
Figure BDA0000136974450000202
Yield 63.0%, ESI-MS (m/z): 528.20[M-Cl] +;
3-(2-furyl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-42)
Figure BDA0000136974450000203
Yield 55.0%, ESI-MS (m/z): 474.15[M-Cl] +;
3-(2-thienyl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-43)
Figure BDA0000136974450000204
Yield 72.0%, ESI-MS (m/z): 490.20[M-Cl] +;
3-(3-thienyl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-44)
Figure BDA0000136974450000205
Yield 70.3%, ESI-MS (m/z): 490.15[M-Cl] +;
3-(pyridin-3-yl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-45)
Figure BDA0000136974450000211
Yield 62.5%, ESI-MS (m/z): 485.20[M-Cl] +;
3-(pyridin-3-yl)-3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-46)
Figure BDA0000136974450000212
Yield 60.0%, ESI-MS (m/z): 485.20[M-Cl] +;
3-(pyridin-4-yl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-47)
Figure BDA0000136974450000213
Yield 65.5%, ESI-MS (m/z): 485.25[M-Cl] +;
3-(pyridin-4-yl)-3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-48)
Figure BDA0000136974450000214
Yield 57.0%, ESI-MS (m/z): 485.20[M-Cl] +;
3-(cumarone-4-yl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-49)
Figure BDA0000136974450000215
Yield 85.5%, ESI-MS (m/z): 524.25[M-Cl] +;
3-(cumarone-4-yl)-3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-50)
Figure BDA0000136974450000221
Yield 87.0%, ESI-MS (m/z): 524.20[M-Cl] +;
3-(the chloro-cumarone-4-of 7-yl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-51)
Yield 90.0%, ESI-MS (m/z): 558.20[M-Cl] +;
3-(the chloro-cumarone-4-of 7-yl)-3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-52)
Figure BDA0000136974450000223
Yield 93.2%, ESI-MS (m/z): 558.10[M-Cl] +;
3-(2,3-Dihydrobenzofuranes-4-yl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-53)
Figure BDA0000136974450000224
Yield 87.5%, ESI-MS (m/z): 526.20[M-Cl] +;
3-(2,3-Dihydrobenzofuranes-4-yl)-3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-54)
Yield 85.6%, ESI-MS (m/z): 526.20[M-Cl] +;
3-(2,3-Dihydrobenzofuranes-5-yl)-3-[6-[3-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-55)
Figure BDA0000136974450000231
Yield 80.8%, ESI-MS (m/z): 526.25[M-Cl] +;
3-(2,3-Dihydrobenzofuranes-5-yl)-3-[6-[4-[(4,5-dihydro-1H-imidazoles-2-yl) amino] benzoylamino]-1-oxygen isoindole-2-yl] propionic salt hydrochlorate (I-56)
Figure BDA0000136974450000232
Yield 82.0%, ESI-MS (m/z): 526.15[M-Cl] +.
Embodiment 10 biological activity test results
Table one: the inhibiting rate (n=3) that part target compound adheres on Fibronectin melanoma M21 cell
Conclusion: disclosed in this invention 1, the significantly adhesion of check melanin oncocyte M21 to fibronectin of 3-dihydro-1-oxygen-2H-isoindoles compound (I) or its pharmacy acceptable salt, the inhibition activity of part target compound is compared with positive control medicine---and cyclo (RGDfV) is strong.

Claims (3)

  1. One kind prepare as general formula ( i) shown in 1,3-dihydro-1-oxygen-2 hthe method of-isoindoles compound and pharmacy acceptable salt thereof,
    Figure 363898DEST_PATH_IMAGE001
    In formula: R 1represent H, phenyl, 2-furyl, 2-thienyl, 3-thienyl, 3-pyridyl, 4-pyridyl, 3,4-methylenedioxyphenyl base, 2,3-methylenedioxyphenyl base,
    Figure 314537DEST_PATH_IMAGE002
    ,
    Figure 790517DEST_PATH_IMAGE003
    ,
    Figure 611843DEST_PATH_IMAGE004
    , or
    Figure 585801DEST_PATH_IMAGE006
    ; R 3, R 4, R 5represent independently of one another H, C 1~ C 6alkyl, C 1~ C 6alkoxyl group, hydroxyl, halogen, amino, nitro, cyano group, carboxyl, CF 3, NR 7r 8, R 6represent H, C 1~ C 6alkyl, C 1~ C 6alkoxyl group, halogen, nitro, cyano group or CF 3, R 7, R 8represent independently of one another C 1~ C 6alkyl, R 3, R 4, R 5, R 6can be at any possible position of phenyl ring, R 3, R 4, R 5can be identical, also can be different; R 2represent
    Figure 6418DEST_PATH_IMAGE007
    ,
    Figure 947829DEST_PATH_IMAGE008
    ,
    Figure 654754DEST_PATH_IMAGE009
    , , n represents that 1-3, m represent 0-2, R 9represent C 1~ C 6alkyl, halogen, hydroxyl or CF 3;
    It is characterized in that comprising the steps:
    Figure 273134DEST_PATH_IMAGE011
    ( a) with 2-formyl radical-5-nitrobenzoic acid ( 4) and Beta-alanine methyl ester derivation ( 5) be starting raw material, in suitable solvent through reduction, cyclization obtain 3-(6-nitro-1-oxygen isoindole-2-yl) methyl propionate ( 6);
    ( b) gained intermediate ( 6) be amino through the reduction of chemical reduction or catalytic hydrogenation by nitroreduction, obtain 3-(6-amino-1-oxygen isoindole-2-yl) methyl propionate ( 7);
    ( c) intermediate ( 7) with containing the carboxylic acid cpd of guanidine radicals ( 8) condensation under condensing agent existence condition, obtain 1,3-dihydro-1-oxygen-2 h-isoindole methyl compound ( 9);
    ( d) ( 9) through basic hydrolysis, acid neutralization, obtain 1,3-dihydro-1-oxygen-2 h-isoindoles compound ( i).
  2. 2. as claimed in claim 11,3-dihydro-1-oxygen-2 h-isoindoles compound ( i) and the preparation method of pharmacy acceptable salt, it is characterized in that step ( a) in, reaction solvent for use is: C 1-8fatty alcohol, n,N-dimethyl formamide, ether, isopropyl ether, methyl tertiary butyl ether, tetrahydrofuran (THF), glycol dimethyl ether, C 1-6lipid acid, C 1-6lipid acid and C 1-6ester that fatty alcohol forms, methylene dichloride, chloroform, 1,2-ethylene dichloride, benzene,toluene,xylene, chlorobenzene, orthodichlorobenzene or acetonitrile; Reductive agent used is: KBH 4, NaBH 4, LiBH 4, NaBH 3cN; 2-formyl radical-5-nitrobenzoic acid ( 4), Beta-alanine methyl ester derivation ( 5) and the molar feed ratio of reductive agent be 1.0:1.0 ~ 5.0:0.5 ~ 5.0; Temperature of reaction is-20 ℃ ~ 120 ℃; Reaction times is 30 minutes ~ 72 hours;
    Step ( b) in, while using chemical reduction method, reaction solvent for use is: C 1~ C 6fatty alcohol, tetrahydrofuran (THF), ether, C 1-6lipid acid, C 1-6lipid acid and C 1-6ester that fatty alcohol forms, benzene, toluene, Isosorbide-5-Nitrae-dioxane, glycol dimethyl ether, methylene dichloride, chloroform, 1, the aqueous hydrochloric acid that 2-ethylene dichloride, concentration are 1%-36%, the aqueous ammonium chloride solution that concentration is 1%-30% or the mixture of above-mentioned solvent; Reductive agent used is: zinc powder, iron powder or tindichloride; Compound ( 6) with the molar feed ratio of reductive agent be 1.0:1.0 ~ 10.0; Temperature of reaction is 0 ℃ ~ 150 ℃; The reduction reaction time is 0.5 ~ 72 hour;
    While reduction by catalytic hydrogenation, reaction solvent for use is: C 1-8fatty alcohol, ether, isopropyl ether, methyl tertiary butyl ether, tetrahydrofuran (THF), glycol dimethyl ether, C 1-6lipid acid, C 1-6lipid acid and C 1-6ester that fatty alcohol forms, benzene,toluene,xylene or acetonitrile; Used catalyst is: 1% ~ 30%Pd-C, 1% ~ 30% Pd (OH) 2-C, Raney-Ni; Compound ( 6) with the mass ratio of catalyzer be 1.0:0.01 ~ 1.0; Reaction pressure is normal pressure ~ 10.0 MPa; Temperature of reaction is room temperature ~ 150 ℃; Reaction times is 1 ~ 48 hour.
  3. 3. as claimed in claim 11,3-dihydro-1-oxygen-2 h-isoindoles compound ( i) and the preparation method of pharmacy acceptable salt, it is characterized in that step ( c) in, reaction solvent for use is: pyridine, water, C 1-8fatty alcohol, n,N-dimethyl formamide, C 3-8aliphatic ketone, ether, isopropyl ether, methyl tertiary butyl ether, tetrahydrofuran (THF), glycol dimethyl ether, C 1-6lipid acid, C 1-6lipid acid and C 1-6ester that fatty alcohol forms, methylene dichloride, chloroform, 1,2-ethylene dichloride, benzene,toluene,xylene, chlorobenzene, orthodichlorobenzene or acetonitrile, reaction can be carried out in above-mentioned single solvent, also can in above-mentioned mixed solvent, carry out, and mixed solvent volume ratio is 1:0.1 ~ 10; Condensing agent used is: n-ethoxycarbonyl-2-oxyethyl group-1,2-dihydroquinoline, dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylamine propyl) carbodiimide hydrochloride, diethyl phosphorocyanidate, 2-chloro-4,6-dimethoxy-1,3,5-triazine, chlorination 4-(4,6-dimethoxy-1,3,5-triazines-2-yl)-4-methylmorpholine salt; Compound ( 7): compound ( 8): the molar feed ratio of condensing agent is 1.0:1.0 ~ 4.5:1.0 ~ 4.5; Setting-up point is 0 ~ 130 ℃; Condensation reaction time is 30 minutes ~ 72 hours;
    Step ( d) in, being hydrolyzed alkali used is basic metal or alkaline earth metal hydroxides, basic metal or alkaline earth metal carbonate, basic metal or alkali metal bicarbonates; Alkali and compound ( 9) molar feed ratio be 1.0 ~ 5.0:1.0; Hydrolysising reacting temperature is room temperature ~ 150 ℃; Hydrolysis time is 0.5 ~ 24 hour.
CN201210038183.7A 2012-02-21 2012-02-21 1,3-dihydro-1-oxo-2H-isobenzazole compounds as well as preparation method and use thereof Expired - Fee Related CN102603610B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201410270438.1A CN104045594B (en) 2012-02-21 2012-02-21 One class 1,3-dihydro-1-oxygen-2H-isoindoles compound and application thereof
CN201210038183.7A CN102603610B (en) 2012-02-21 2012-02-21 1,3-dihydro-1-oxo-2H-isobenzazole compounds as well as preparation method and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210038183.7A CN102603610B (en) 2012-02-21 2012-02-21 1,3-dihydro-1-oxo-2H-isobenzazole compounds as well as preparation method and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410270438.1A Division CN104045594B (en) 2012-02-21 2012-02-21 One class 1,3-dihydro-1-oxygen-2H-isoindoles compound and application thereof

Publications (2)

Publication Number Publication Date
CN102603610A CN102603610A (en) 2012-07-25
CN102603610B true CN102603610B (en) 2014-07-09

Family

ID=46521452

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210038183.7A Expired - Fee Related CN102603610B (en) 2012-02-21 2012-02-21 1,3-dihydro-1-oxo-2H-isobenzazole compounds as well as preparation method and use thereof

Country Status (1)

Country Link
CN (1) CN102603610B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103159667B (en) * 2013-03-15 2015-04-01 四川大学 6-guanidyl-2H-isoindole compound as well as preparation method and application thereof
CN105294533A (en) * 2015-12-02 2016-02-03 宋彤云 Pharmaceutical composition for treating bone diseases
CN108530497A (en) * 2018-04-09 2018-09-14 江南大学 Glycoprotein amino acid and the oligosaccharides analogies prepared using glycoprotein amino acid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2331461C (en) * 1998-05-11 2008-10-07 Entremed, Inc. Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
CN1190420C (en) * 2001-11-07 2005-02-23 四川大学 Non-peptide neomatal vascularization inhibitor
US7405237B2 (en) * 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use

Also Published As

Publication number Publication date
CN102603610A (en) 2012-07-25

Similar Documents

Publication Publication Date Title
JP6995101B2 (en) N-((heta) arylmethyl) -heteroaryl-carboxamide compound as a plasma kallikrein inhibitor
US10919937B2 (en) Bicyclic peptide ligands and uses thereof
TWI337609B (en) Pyridine [3,4-b] pyrazinones
RU2721774C1 (en) Pyrimido[5,4-b]indolizine or pyrimido[5,4-b]pyrrolizine compound, method for production thereof and use thereof
TW201311685A (en) Imidazopyridine compounds
AU2005254751B2 (en) Pyrimidine derivatives antagonists of vitronectin receptor
KR20190033487A (en) Pyrazole derivatives as plasma calicain inhibitors
US10202373B2 (en) Heteroaryls and uses thereof
RU2672582C2 (en) Bicyclic inhibitors
CN103097340A (en) Therapeutically active compositions and their method of use
TW201124416A (en) Heterocyclic compounds useful as PDK1 inhibitors
CN101981027A (en) Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
TW200539880A (en) Beta-carbolines useful for treating inflammatory disease
WO2020038460A1 (en) Novel quinoline derivative inhibitor
TW201139410A (en) Substituted naphthalenyl-pyrimidine compounds
CN102603610B (en) 1,3-dihydro-1-oxo-2H-isobenzazole compounds as well as preparation method and use thereof
CN108727361A (en) Indole amine 2,3-dioxygenase inhibitor and application
AU2014211728A1 (en) Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions
WO2017088723A1 (en) Substituted triazolopiperazine parp inhibitor, preparation method therefor, and use thereof
JP3936844B2 (en) Integrin receptor ligand
JP2023535932A (en) tricyclic heterocycle
WO2021224291A1 (en) Tricyclic heterocycles useful as tead binders
CA2841897A1 (en) Novel compound having parp inhibitory activity
WO2016050201A1 (en) High selectivity substituted pyrimidine pi3k inhibitor
CN104045594A (en) 1,3-dihydro-1-oxo-2H-isoindole compounds and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140709

Termination date: 20160221

CF01 Termination of patent right due to non-payment of annual fee